Terms ending in 2038
Every in-force patent on 2SEVENTY Bio, Inc.'s record whose computed term ends in 2038, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,365,711 | Tgfbeta Signal Convertor In force · Low confidence | Regeneron Pharmaceuticals, Inc. | In force | Low confidence | |
| US 10,927,367 | CBLB Endonuclease Variants, Compositions, and Methods of Use In force · Low confidence | Regeneron Pharmaceuticals, Inc. | In force | Low confidence | |
| US 12,109,234 | Anti-Bcma Car T Cell Compositions In force · High confidence | 2SEVENTY Bio, Inc. | In force | High confidence | |
| US 11,654,158 | TGFBeta SIGNAL CONVERTOR In force · High confidence | Regeneron Pharmaceuticals, Inc. | In force | High confidence | |
| US 11,365,226 | PD-1 Homing Endonuclease Variants, Compositions, and Methods of Use In force · High confidence | Regeneron Pharmaceuticals, Inc. | In force | High confidence | |
| US 10,793,843 | CBLB Endonuclease Variants, Compositions, and Methods of Use In force · Medium confidence | Regeneron Pharmaceuticals, Inc. | In force | Medium confidence | |
| US 12,686,711 | Daric Interleukin Receptors In force · High confidence | Regeneron Pharmaceuticals, Inc. | In force | High confidence | |
| US 11,732,255 | CBLB Endonuclease Variants, Compositions, and Methods of Use In force · Medium confidence | Regeneron Pharmaceuticals, Inc. | In force | Medium confidence |
8 of 8 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by 2SEVENTY Bio, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.